Brian Nichlos : GILD Is A Monster of a Company. LINK
( Just Got Back in GILD and Saw This, Had To Post, Looks Great )
3 Upgrades on Friday Worth Noting
By Brian Nichols - May 20, 2013 |
This Pharma Company Just Keeps Getting Better
Gilead Sciences (NASDAQ: GILD) had seen a bit of a pullback on Thursday, but then erased those losses with gains on Friday after UBS raised its price target to $67 and reiterated its “Buy” rating. The company dominates the HIV market, among others (including an upcoming entrance into oncology), and after a survey of top-volume prescribers the firm is optimistic of the company’s TAF HIV treatment.
The firm went on to say that it could be a next-generation replacement for Viread. As an investor, I take analyst calls more seriously where channel checks or surveys are performed, as they indicate future trends. Gilead is a monster of a company and is well on its way to becoming the next Pfizer. The company controls every industry where it develops drugs, and I agree with UBS, and believe that $67 is a generous target if in fact TAF will be as warmly welcomed as expected